BAR-501, a UDCA derivative, is a selective GPBAR1 agonist devoid of any FXR agonistic activity. BAR-501 effectively transactivates GPBAR1 in HEK293 cells overexpressing a CRE along with GPBAR1, with a EC50 of 1 μM. Besides, it protects against development of portal hypertension in rodent models of liver injury and endothelial dysfunction.
Products > Drug Discovery > Impurities > Cardiovascular And Blood System > Bar-501 and Impurities | Products > Drug Discovery > Inhibitor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.